Vistagen's Fasedienol Meets Key ICH E1 Safety Milestones with Over 1,500 Subjects
VTGN sits 28% above its 52-week low of $0.43.
Summary
Vistagen's fasedienol nasal spray program has met ICH E1 minimum patient safety exposure recommendations, with over 1,500 subjects exposed, including long-term data. This news reports on the 8-K filed earlier today and follows the completion of the PALISADE-4 Phase 3 trial's randomized portion in early May and preliminary positive safety data from its open-label extension. Meeting these safety milestones is a critical step for building a robust safety profile required for a potential New Drug Application. However, the company still needs to align with the FDA on specific patient exposure requirements for NDA submission. Topline results for PALISADE-4 are expected in Q2 2026, and Phase 2 Repeat Dose results in Q3 2026.
At the time of this announcement, VTGN was trading at $0.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.3M. The 52-week trading range was $0.43 to $5.14. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.